I think the N-Assay could be sold for much more considering all the health complications it could prevent with early detection and treatment. Without a hard analysis of what the savings on prevention could be (and considering the savings on just identification of bacteria and treatment), guessing at the price of the N-Assay kit is arbitrary. I think $450 per kit still sounds cheap for all the down the line savings. It doesn't sound too expensive until it gets to around $2,000 per kit to me.
That translates to a LOT of money in revenues.
Using Available Shares of 200M to keep things simple, as soon as the first three (?) N-Assay kits addressing the bacteria in Dr. Faro's poster presentation becomes commercially available (followed by quick adoption by hospitals and the like), the price tag to buy Nanologix could easily be justified into the double digits.